Lung Cancer Treatment in Gurugram
Lung cancer is among the most common cancers in Indian men, and one of the areas where treatment has changed most dramatically in the last decade. Dr. Sandeep Ramawat treats both non-small cell (NSCLC) and small cell (SCLC) lung cancer at the American Oncology Institute, Gurugram.
What lung cancer treatment involves
Treatment is decided by the type of lung cancer, its stage, and the molecular profile of the tumour. After a biopsy and staging scans, the plan may combine systemic therapy with surgery or radiation. For many patients today, treatment is no longer chemotherapy alone.
Molecular testing and targeted therapy
Modern lung cancer care begins with molecular testing. Tumours driven by specific genetic alterations, such as ALK rearrangement or EGFR mutation, often respond to oral targeted therapy rather than conventional chemotherapy. Dr. Ramawat has presented nationally on the role of ALK inhibitors in ALK-positive lung cancer at the Radiation Oncology Meet, Dehradun.
Immunotherapy for lung cancer
Immunotherapy helps the body’s own immune system recognise and attack cancer cells. For a subset of lung cancer patients it has meaningfully changed outcomes, and it may be used alone or alongside chemotherapy depending on the tumour’s characteristics.
When to see a lung cancer specialist
A persistent cough lasting more than three weeks, coughing up blood, unexplained weight loss, breathlessness, or a lung shadow found on a scan all warrant an oncology opinion. Screening with low-dose CT may be advised for long-term smokers.
Consulting for lung cancer in Gurugram
Dr. Sandeep Ramawat consults at the American Oncology Institute, Aarvy Healthcare Super Specialty Hospital, Sector 90, Gurugram. OPD hours are Monday to Saturday, 9:00 am - 6:00 pm. Please bring your biopsy report, imaging and any prior treatment records to the first visit.
Appointments: +91 95606 83949 · drsandeepramawat@gmail.com
Frequently asked questions
Stage IV lung cancer is treatable in many cases. With targeted therapy and immunotherapy, a number of patients with advanced lung cancer now achieve long-term disease control and remissions that were uncommon a decade ago. The specific outlook depends on the tumour type and molecular profile.
For non-small cell lung cancer it is strongly advised. Molecular testing identifies whether the tumour carries a targetable alteration such as ALK or EGFR, which can completely change the recommended treatment and the results the patient can expect.
No. Depending on the stage and molecular profile, treatment may be oral targeted therapy, immunotherapy, chemotherapy, or a combination. Some early-stage patients are treated primarily with surgery or radiation, with systemic therapy added as needed.
Speak to Dr. Ramawat
Consultations at the American Oncology Institute, Gurugram. Call directly or send your details on WhatsApp.